See more : Blackhawk Growth Corp. (BLR.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Accelerate Diagnostics, Inc. (AXDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accelerate Diagnostics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Public Joint Stock Company Aeroflot – Russian Airlines (AFLT.ME) Income Statement Analysis – Financial Results
- Medexus Pharmaceuticals Inc. (MDP.TO) Income Statement Analysis – Financial Results
- AML3D Limited (AL3.AX) Income Statement Analysis – Financial Results
- Advent Technologies Holdings, Inc. (ADNWW) Income Statement Analysis – Financial Results
- Winmill & Co. Incorporated (WNMLA) Income Statement Analysis – Financial Results
Accelerate Diagnostics, Inc. (AXDX)
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 12.75M | 11.78M | 11.17M | 9.30M | 5.67M | 4.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 475.52K | 183.13K | 212.70K | 502.11K | 118.61K | 850.57K | 653.98K | 855.66K | 1.57M | 2.90M | 7.38M | 2.50M | 2.10M |
| Cost of Revenue | 9.51M | 9.45M | 12.16M | 6.71M | 4.90M | 3.19M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.65K | 56.65K | 41.60K | 155.51K | 65.63K | 148.54K | 184.25K | 534.64K | 644.01K | 1.23M | 1.15M | 300.00K | 300.00K |
| Gross Profit | 2.55M | 3.30M | -381.00K | 4.46M | 4.40M | 2.48M | 3.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 465.87K | 126.48K | 171.10K | 346.60K | 52.98K | 702.03K | 469.73K | 321.02K | 923.38K | 1.67M | 6.23M | 2.20M | 1.80M |
| Gross Profit Ratio | 21.15% | 25.90% | -3.23% | 39.94% | 47.33% | 43.79% | 76.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 97.97% | 69.07% | 80.44% | 69.03% | 44.67% | 82.54% | 71.83% | 37.52% | 58.91% | 57.60% | 84.37% | 88.00% | 85.71% |
| Research & Development | 25.35M | 26.92M | 21.94M | 21.26M | 25.35M | 27.64M | 22.30M | 28.20M | 26.02M | 20.05M | 10.67M | 432.00K | 455.00K | 501.60K | 745.93K | 880.98K | 991.58K | 2.16M | 1.30M | 554.42K | 568.87K | 326.58K | 123.49K | 0.00 | 0.00 | 68.77K | 100.00K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 2.95M | 810.08K | 869.35K | 919.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 709.01K | 1.53M | 997.83K | 956.67K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.32K | 9.62K | 1.40K | 13.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 288.86K | 817.35K | 1.20M | 1.29M | 0.00 | 0.00 |
| SG&A | 31.23M | 39.19M | 49.24M | 46.90M | 51.89M | 55.21M | 45.06M | 36.20M | 17.88M | 10.70M | 4.31M | 2.95M | 819.70K | 870.75K | 932.99K | 1.02M | 935.67K | 903.65K | 994.98K | 978.37K | 1.19M | 742.07K | 997.87K | 2.34M | 2.20M | 2.25M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -227.00K | -20.00K | -60.00K | -14.00K | -28.00K | -184.00K | 2.35M | 1.79M | 888.00K | -4.45K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 293.11K | 490.02K | 170.38K | 638.43K | 895.80K | 0.00 | 0.00 | 200.00K | 100.00K |
| Operating Expenses | 56.58M | 66.11M | 71.18M | 68.16M | 77.23M | 82.85M | 67.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.19M | 2.24M | 3.38M | 2.61M | 1.83M | 2.25M | 1.24M | 1.76M | 3.24M | 2.20M | 2.32M | 1.40M | 600.00K |
| Cost & Expenses | 66.09M | 75.56M | 83.34M | 74.87M | 82.13M | 86.04M | 68.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.20M | 2.30M | 3.42M | 2.76M | 1.89M | 2.40M | 1.42M | 2.29M | 3.88M | 3.42M | 3.47M | 1.70M | 900.00K |
| Interest Income | 1.12M | 551.00K | 88.00K | 855.00K | 2.81M | 2.85M | 908.00K | 494.00K | 74.00K | 64.00K | 33.49K | 17.00K | 16.09K | 6.05K | 18.33K | 63.08K | 0.00 | 0.00 | 0.00 | 64.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.74M | 3.77M | 15.55M | 15.55M | 14.26M | 10.11M | 0.00 | 23.00K | 23.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.25M | 3.00M | 2.52M | 3.00M | 2.60M | 2.56M | 2.20M | 2.35M | 1.79M | 888.00K | 362.50K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 282.79K | 293.32K | 170.38K | 638.43K | 895.80K | 702.53K | 328.01K | 200.00K | 100.00K |
| EBITDA | -49.77M | -55.80M | -59.59M | -59.66M | -67.56M | -75.44M | -61.34M | -64.15M | -43.68M | -30.10M | -14.92M | -3.15M | -153.53K | 873.28K | -409.03K | -1.43M | -1.80M | -2.71M | -1.95M | -1.49M | -1.64M | -598.92K | -800.34K | -1.42M | 175.64K | 4.24M | 1.00M | 1.30M |
| EBITDA Ratio | -412.73% | -466.44% | -585.42% | -536.57% | -725.33% | -1,322.59% | -1,534.76% | -25,876.42% | -29,716.33% | -25,050.82% | -30,911.59% | -498.73% | -14.99% | 37.82% | -28.00% | -298.12% | -1,026.29% | -1,354.58% | -391.97% | -1,255.86% | -129.90% | -69.93% | 20.13% | -108.49% | 6.06% | 57.43% | 28.00% | 61.90% |
| Operating Income | -54.03M | -62.81M | -71.56M | -63.70M | -72.83M | -80.37M | -64.18M | -66.50M | -45.55M | -31.52M | -15.31M | -5.35M | -409.43K | 611.79K | -679.12K | -1.73M | -2.11M | -3.20M | -2.26M | -1.77M | -1.55M | -769.30K | -1.44M | -2.32M | -526.89K | 3.91M | 800.00K | 1.20M |
| Operating Income Ratio | -448.03% | -492.51% | -607.37% | -570.53% | -783.38% | -1,417.44% | -1,536.56% | -27,032.93% | -30,985.71% | -25,833.61% | -31,709.35% | -2,267.80% | -36.52% | 27.24% | -53.48% | -363.31% | -1,154.63% | -1,506.59% | -449.89% | -1,494.69% | -181.83% | -117.63% | -168.15% | -147.83% | -18.18% | 52.99% | 32.00% | 57.14% |
| Total Other Income/Expenses | -6.74M | 235.00K | -6.10M | -14.50M | -11.59M | -7.75M | 649.00K | 394.00K | 51.00K | -470.00K | 29.00K | 41.28K | 30.66K | 29.95K | -53.41K | 47.29K | 190.24K | 173.90K | 168.15K | 74.09K | 151.34K | 50.54K | -426.14K | 861.08K | 565.94K | 536.88K | 400.00K | -1.20M |
| Income Before Tax | -60.77M | -62.57M | -77.66M | -78.20M | -84.42M | -88.12M | -63.53M | -66.11M | -45.50M | -31.46M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -1.70M | -1.40M | -718.76K | -1.86M | -1.46M | 39.05K | 4.45M | 1.20M | 1.10M |
| Income Before Tax Ratio | -503.92% | -490.67% | -659.12% | -700.43% | -907.99% | -1,554.06% | -1,521.02% | -26,872.76% | -30,951.02% | -25,786.89% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -1,432.23% | -164.04% | -109.91% | -217.95% | -92.89% | 1.35% | 60.26% | 48.00% | 52.38% |
| Income Tax Expense | 850.00K | -77.00K | 45.00K | 5.00K | -111.00K | 211.00K | -651.00K | 267.00K | 74.00K | -527.00K | -22.13K | 1.96M | 378.76K | -641.75K | 714.20K | -47.29K | -190.24K | -173.90K | -168.15K | -789.40K | -19.43K | -318.03K | -318.19K | -533.46K | 31.38K | 1.57M | 200.00K | -1.10M |
| Net Income | -61.62M | -62.49M | -77.70M | -78.21M | -84.31M | -88.33M | -62.88M | -66.37M | -45.50M | -30.93M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -909.42K | -1.38M | -400.73K | -1.55M | -922.54K | 70.43K | 2.88M | 1.00M | 1.10M |
| Net Income Ratio | -510.97% | -490.06% | -659.50% | -700.47% | -906.80% | -1,557.78% | -1,505.43% | -26,981.30% | -30,951.02% | -25,354.92% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -766.71% | -161.75% | -61.28% | -180.76% | -58.86% | 2.43% | 39.00% | 40.00% | 52.38% |
| EPS | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.02 | -1.19 | 0.10 | 3.80 | 1.50 | 8.80 |
| EPS Diluted | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.01 | -1.19 | 0.10 | 3.50 | 1.20 | 6.80 |
| Weighted Avg Shares Out | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 766.80K | 776.71K | 782.19K | 761.05K | 666.67K | 549.30K |
| Weighted Avg Shares Out (Dil) | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 767.98K | 776.71K | 803.65K | 812.50K | 833.33K | 549.30K |
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Accelerate Diagnostics, Inc. (AXDX) Q2 2023 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2023 Earnings Conference Call August 10, 2023 4:00 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President & Director David Patience - CFO, Principal Financial Officer & Principal Accounting...
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $2.36 per share versus the Zacks Consensus Estimate of a loss of $1.50. This compares to loss of $2.40 per share a year ago.
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
TUCSON, Ariz. , Aug. 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
TUCSON, Ariz. , July 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m.
Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split
TUCSON, Ariz. , July 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at...
Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?
Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
TUCSON, Ariz. , June 13, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement.
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants...
Source: https://incomestatements.info
Category: Stock Reports